ArticlePediatric blood & cancer2008
Valacyclovir and acyclovir pharmacokinetics in immunocompromised children.
Article in Pediatric blood & cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Mitochondrial changes associated with viral infectious diseases in the paediatric population.Reviews in medical virology · 2021Pooled it
- Acute retinal necrosis: Report 1-Epidemiology, clinical profile, and misdiagnosis from the largest Indian case series.Indian journal of ophthalmology · 2026Article
- A quick algorithmic review on management of viral infectious diseases in pediatric solid organ transplant recipients.Frontiers in pediatrics · 2023Review
- Antiviral Therapeutics in Pediatric Transplant Recipients.Infectious disease clinics of North America · 2022Review
- Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.Neuro-oncology · 2019Article
- Delayed allergy to acyclovir revealed by lymphocyte proliferation test.Postepy dermatologii i alergologii · 2018Article
- Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.Biopharmaceutics & drug disposition · 2017Review
- Clinical characteristics and outcomes of varicella zoster virus infection in children with hematologic malignancies in the acyclovir era.Blood research · 2016Article
- Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study.Journal of pharmacokinetics and pharmacodynamics · 2015Article
- Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.Advanced drug delivery reviews · 2014Review
- Safety of short-term valacyclovir as an anti-sickling agent in sickle-cell anemia.Pediatric blood & cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundValacyclovir, an orally administered pro-drug of acyclovir, is utilized in the therapy of herpes simplex and herpes zoster infections. Little data regarding the pharmacokinetics, safety and tolerability are available for pediatric patients. This report describes acyclovir pharmacokinetics following valacyclovir administration in immunocompromised pediatric patients, compares pharmacokinetic parameters following oral valacyclovir and IV acyclovir, and provides a limited assessment of efficacy in the setting of active herpes zoster infection. PROCEDURE: A total of 37 immunocompromised children were enrolled on one of two studies. Pharmacokinetic data are available for 32 patients following valacyclovir (15 mg/kg) administration, 11 of whom also had pharmacokinetic sampling following IV acyclovir administration. Three patients received valacyclovir as treatment for herpes zoster infections.
resultsMean (+/-SD) C(max) values for acyclovir following oral valacyclovir were 18.8 +/- 7 microM with a total exposure of 4,106 +/- 1,519 microM min. The mean bioavailability of acyclovir from valacyclovir was 64%. Grade 1 nausea and emesis, which occurred in five patients was the only valacyclovir-related toxicity. Two of the three patients treated for herpes zoster had complete scabbing of lesions by day 9.
conclusionValacyclovir (15 mg/kg) was well tolerated in pediatric patients and demonstrated excellent bioavailability. Consideration should be given to the use of oral valacyclovir for the treatment of herpes zoster in clinically stable pediatric oncology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.